BOSTON, March 25, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a Boston-based biopharmaceutical company focused on the global development of biosimilar monoclonal antibodies, today announced that it will host a Key Opinion Leader (KOL) breakfast in New York City focused on offering insights into the evolution of the U.S. regulatory landscape, along with a clinician's perspective on the approval and use of biosimilars. The event and live webcast will take place on Monday, March 30, 2015 from 8:00 to 9:15 a.m. Eastern Time.
The meeting will feature a keynote presentation by Jonathan Kay, MD, Professor of Medicine at the University of Massachusetts Medical School and Director of Clinical Research in the Division of Rheumatology at UMass Memorial Medical Center in Worcester, MA. Both Dr. Kay and members of EPIRUS' management team will be available for questions.
To reserve a place, please contact Veronica Molina at 1-212-915-2567 or via email at vmolina@lifesciadvisors.com. A live webcast and subsequent replay of the event will also be available at EPIRUS' website at http://ir.epirusbiopharma.com/index.cfm. The webcast will be archived on the Company's website for a period of three months. This event is limited to institutional investors and sell-side analysts.
Over the past two decades, Dr. Kay's research has focused on clinical aspects and treatment of rheumatoid arthritis and other forms of inflammatory arthritis, as well as on rheumatologic problems of patients with chronic kidney disease. He has been a principal investigator on over 50 clinical trials of novel therapies for rheumatoid arthritis, osteoarthritis, gout and spondyloarthropathies, such as ankylosing spondylitis. More recently, he has been involved in the development of biosimilars to treat rheumatic diseases. Dr. Kay was a member of the group that developed the 2010 ACR/EULAR Diagnostic and Classification Criteria for Rheumatoid Arthritis. He chairs the Rheumatology Working Group and is a member of the Internal Medicine and Musculoskeletal Topic Advisory Groups for the WHO in its Revision of the International Classification of Diseases (ICD)-11.
About EPIRUS Biopharmaceuticals
EPIRUS Biopharmaceuticals (Nasdaq:EPRS) is a global biosimilar company focused on improving patient access to important medicines. EPIRUS' operationally synergistic pipeline of biosimilar product candidates includes BOW015 (infliximab), BOW050 (adalimumab) and BOW070 (tocilizumab). The reference products for these candidates -- Remicade®, Humira® and Actemra®, respectively -- together generated over $20 billion in global sales for 2013, according to EvaluatePharma®. EPIRUS has developed distinct strategies to access its targeted markets with the goal to build a profitable and sustainable biosimilar business. For more information visit EPIRUS' website at www.epirusbiopharma.com.
Remicade is a registered trademark of Johnson and Johnson (www.jnj.com)
Humira is a registered trademark of AbbVie (www.abbvie.com)
Actemra is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group (www.gene.com)